Evidence map›Paper›PMID 19763850›Full record

ArticleJournal of muscle research and cell motility2009

Characterization of secophalloidin-induced force loss in cardiac myofibrils.

Anna E Bukatina, Gary C Sieck, Kenneth B Campbell, Marek Belohlavek

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of muscle research and cell motility, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Anna E BukatinaDivision of Cardiovascular Diseases, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA. boukatina.anna@mayo.edu
Gary C Sieck
Kenneth B Campbell
Marek Belohlavek

Funding

Diagnosis of Cardiac Viability by Functional UltrasoundR01HL068555 · NHLBI · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI BELOHLAVEK, MAREK · 2002 to 2005
$1.3M
RESPIRATORY MUSCLES DURING DEVELOPMENTR01HL034817 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SIECK, GARY C. · 1986 to 2001
$518k
NHLBI NIH HHS HL34817NHLBI NIH HHS HL68555
6 · The paper itself

Abstract

Secophalloidin (SPH) is known to cause in cardiac myofibrils force without Ca(2+) (half-maximal effect approximately 2 mM) followed by irreversible loss of Ca(2+)-activated force. At maximal Ca(2+) activation, SPH increases force (half-maximal effect < 0.1 mM). We found that SPH at low concentration (0.5 mM) did not cause either force activation or force loss at pCa 8.7, but both of these effects did occur when force was activated by Ca(2+). The force loss was prevented when SPH was applied during rigor or in the presence of 2,3-butanedione monoxime (85 mM). Furthermore, studying muscle in which the force was previously reduced by SPH (up to 50%) did not reveal significant changes in Ca(2+) sensitivity and cooperativity of Ca(2+) activation or qualitative alterations in SPH-induced changes in Ca(2+)-activated contraction. Data suggest that the force loss is mediated by cycling cross-bridges, and might reflect a reduction in force generated by individual cross-bridges.

Indexed as

Actin CytoskeletonAdenosine TriphosphateAnimalsCalciumCalcium SignalingCattleDose-Response Relationship, DrugHydrogen-Ion ConcentrationMuscle ContractionMuscle WeaknessMyocardiumMyocytes, CardiacMyosinsPhalloidineSus scrofaAdenosine TriphosphateCalciumMyosinsPhalloidinesecophalloidin-H-A

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.